Dr. Hyman was the senior study author of a major trial centering on Larotrectinib (LOXO-101) induced durable responses in patients with TRK fusion-positive solid tumors.  The FDA subsequently approved Larotrectinib (Vitrakvi) for cancerous tumors with certain genetic...